Insider Selling: Bolt Biotherapeutics (NASDAQ:BOLT) COO Sells $16,297.88 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) COO Grant Yonehiro sold 4,909 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $3.32, for a total value of $16,297.88. Following the transaction, the chief operating officer directly owned 24,119 shares in the company, valued at approximately $80,075.08. This represents a 16.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Grant Yonehiro also recently made the following trade(s):

• On Friday, September 18th, Grant Yonehiro sold 6,850 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.24, for a total value of $22,194.00.
• On Wednesday, September 16th, Grant Yonehiro sold 1,417 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.77, for a total value of $5,342.09.

Bolt Biotherapeutics Trading Down 1.6%

BOLT stock opened at $3.65 on Thursday. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. Bolt Biotherapeutics, Inc. has a twelve month low of $3.10 and a twelve month high of $7.20. The company has a market cap of $7.04 million, a P/E ratio of -0.22 and a beta of 1.09. The business has a fifty day moving average of $3.82 and a 200-day moving average of $4.28.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. As a group, equities research analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors have recently modified their holdings of BOLT. Nan Fung Group Holdings Ltd bought a new stake in Bolt Biotherapeutics in the 2nd quarter valued at $19,250. Renaissance Technologies LLC increased its holdings in Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after purchasing an additional 22,200 shares in the last quarter. Finally, T3 Companies LLC bought a new position in Bolt Biotherapeutics during the 4th quarter worth about $208,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BOLT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Finally, Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $22.00 target price for the company. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and an average price target of $14.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.